Emerging Approaches to the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis

Victor J Thannickal, MD
Professor of Medicine and Pathology
Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease
Director, Division of Pulmonary, Allergy, and Critical Care
Vice Chair for Research, Department of Medicine
University of Alabama at Birmingham

Wednesday, December 11, 2019 @ 3-4 pm
Fitkin Amphitheatre

Moderator: Erica Herzog, MD
There is no corporate support for this activity
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ASSESSMENT
Recognition of the rising incidence/prevalence of IPF; new approaches to diagnosis; and new concepts of disease pathogenesis and treatment.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will:
1. Recognize IPF as a disease in aging.
2. Understand current approach to diagnosis.
3. Appreciate emerging concepts of pathogenesis and development of novel therapies.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Richard Matthay, MD, Course Director – No conflicts of interest
Victor Thannickal, MD – Boehringer-Ingelheim, Blade Therapeutics, Versant Venture

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.